Although nanosized urinary extracellular vesicles (uEVs) are increasingly used for biomarker discovery, their isolation currently relies on time-consuming techniques hindering high-throughput application. To navigate this problem, we designed an immunoassay to isolate, quantify, and normalize uEV proteins. The uEV immunoassay consists of a biotinylated CD9 antibody to isolate uEVs, an antibody against the protein of interest, and two conjugated antibodies to quantify the protein of interest and CD9. As a proof of principle, the immunoassay was developed to analyze the water channel aquaporin-2 (AQP2) and the sodium-chloride cotransporter (NCC). CD9 was used as a capture antibody because immunoprecipitation showed that anti-CD9 antibody, but not anti-CD63 antibody, isolated AQP2 and NCC. CD9 correlated strongly with urine creatinine, allowing CD9 to be used for normalization of spot urines. The uEV immunoassay detected AQP2 and NCC with high sensitivity, low coefficients of variance, and stability in dilution series. After water loading in healthy subjects, the uEV immunoassay detected decreases in AQP2 and NCC equally well as the traditional method using ultracentrifugation and immunoblot. The uEV immunoassay also reliably detected lower and higher AQP2 or NCC levels in uEVs from patients with pathological water or salt reabsorption, respectively. In summary, we report a novel approach to analyze uEVs that circumvents existing isolation and normalization issues, requires small volumes of urine, and detects anticipated changes in physiological responses and clinical disorders.
aquaporin-2; biomarker; CD9; exosomes; microvesicles; sodiumchloride cotransporter EXTRACELLULAR VESICLES (EVs), including exosomes, are nanosized lipid membrane vesicles released by cells (22) . They have been identified in all biofluids, including urine (16) . EVs contain proteins and nucleic acids, which may reflect the physiological and pathophysiological state of the cell from which they were released. Therefore, EVs have sparked interest with regard to biomarker discovery (12, 22) . Urinary extracellular vesicles (uEVs) have the advantage that they can be obtained noninvasively and may be of special interest for disorders of the kidney or urinary tract (4, 18) . Indeed, several disease biomarkers have recently been reported in uEVs (6, 17, 21) . Ultracentrifugation followed by immunoblotting is currently the most widely used method to isolate uEVs and quantify proteins of interest (1) . Other techniques to isolate uEVs rely on filtration, precipitation, or size exclusion chromatography, and also require immunoblotting for protein quantification (4, 18) . All of these techniques are time consuming and require large starting volumes of urine, hampering highthroughput clinical application. Here, we report a novel approach using an enzyme-linked immunosorbent assay (ELISA) combined with a time-resolved fluorescence immunoassay to isolate uEVs, requiring small volumes of whole urine and allowing quantification and normalization of uEV proteins of interest. For proof-ofconcept of the immunoassay, we assessed the regulation of the water channel aquaporin-2 (AQP2) and the sodium-chloride cotransporter (NCC) because these two proteins have previously been identified in uEVs and are relevant in physiological and pathophysiological settings (16, 21) .
MATERIALS AND METHODS
Urine samples. All urine samples were collected with protease inhibitors (Roche cOmplete, Woerden, The Netherlands) and centrifuged (3,000 g for 20 min) to remove cells and cell debris and were stored at Ϫ80°C. Urine samples were then used for the uEV immunoassay (100 l/well in duplicate or triplicate) or isolation of uEVs using high-speed and ultracentrifugation (40 ml/sample), as described previously (21). uEVs isolated by ultracentrifugation were solubilized and prepared for immunoblotting. For immunoprecipitation, we used the Dynabeads protein G immunoprecipitation kit according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA). The following antibodies were used for immunoprecipitation: mouse anti-CD9 (clone 209306; R&D Systems, Minneapolis, MN), anti-CD63 (clone H5C6; BD Pharmingen, San Jose, CA), rabbit anti-ALIX (clone HPA011905; Sigma-Aldrich, St. Louis, MO), and rabbit anti-AQP2 and anti-NCC (see below). Urine creatinine and osmolality were measured by our clinical chemistry department using CREP2 Cobas (Roche) and the Arkray Osmo Station (Menarini Diagnostics, Florence, Italy).
uEV immunoassay. Biotin-labeled mouse anti-human CD9 antibodies (clone SN4 C3-3A2; eBioscience, San Diego, CA) in Red Buffer containing 0.01% Tween 40 (Kaivogen, Turku, Finland) were added to neutravidin-coated plates (Thermo Fisher) and incubated overnight at 4°C with gentle shaking. After 100 l of urine sample were incubated in the wells for 1 h, captured uEVs were lysed by 0.01% SDS (10 min incubation with gentle shaking). Subsequently, rabbit anti-human AQP-2 or NCC, both generated by one of the investigators, was added to the wells (1 h incubation). Anti-AQP2 antibody was described before (13) , and anti-NCC antibody was raised in rabbit targeting the peptide RRDCPWKISDEEINKNR. The antibody was confirmed to be specific for NCC using immunohistochemistry, immunoblotting of kidney lysates and NCC-transfected/nontransfected cells, or immunoprecipitation followed by protein mass spectrometry (data not shown). Finally, the donkey anti-rabbit horseradish peroxidase (HRP)-conjugated antibody (clone poly4064; Biolegend, San Diego, CA) followed by the Europium-conjugated anti-CD9 antibody [labeled as described before (3); R&D Systems] were added to the wells (each for 1 h). Each incubation step (urine and antibodies) was followed by six washes with wash buffer (Kaivogen). Addition of ECL followed by enhancement solution (Perkin-Elmer, Turku, Fin-land) allowed detection of signals at 445 (1 ms) and 615 (time resolved) nm by the Wallac Victor 2 multilabel counter (PerkinElmer). For all immunoassay results, we report the remaining signal after subtracting PBS signal.
Healthy subjects and patients. The medical ethics committee approved the water-loading experiment and urine collections in patients (MEC-2015-204) . Healthy subjects (no medical history, no medication) underwent thirsting (10:00 PM to noon) and then drank 20 ml/kg water within 30 min. Spot urine samples were obtained at five time points (10:00 AM, noon, 2:00 PM, 3:00 PM, and 5:00 PM). Nine patients were recruited from our outpatient clinic and included patients with central diabetes insipidus (one patient due to AVP-NPII mutation, one patient due to hypophysectomy), nephrogenic diabetes insipidus (one patient due to AVPR2 mutation, one patient with clinical phenotype and family history consistent with nephrogenic diabetes insipidus, mutation analysis pending), syndrome of inappropriate antidiuresis (one patient due to pituitary adenoma, one patient due to subdural hematoma), Gitelman syndrome (two patients with SLC12A3 mutation), and familial hyperkalemic hypertension (one patient due to KLHL3 mutation).
RESULTS

Development and validation of uEV immunoassay.
CD9 and CD63 are commonly used as uEV markers and are thought to play a role in the biogenesis of uEVs (19) . We first isolated uEVs from human urine by immunoprecipitation using antibody-coated magnetic beads to analyze if CD9 ϩ and CD63 ϩ uEVs express AQP2 or NCC (Fig. 1A ). AQP2 and NCC were present in CD9 ϩ but not in CD63 ϩ uEVs. Analysis of ALIX, another uEV marker protein, suggested a lower concentration of CD63 ϩ uEVs. This is in agreement with tissue distribution, since CD63 is low in abundance in the kidney but highly expressed in bladder and prostate (3, 20) . Therefore, we selected CD9 as our capture antibody for uEVs. Figure 1B shows the design of our sandwich uEV immunoassay. The uEV immunoassay included the following four antibodies: 1) a biotinylated anti-CD9 antibody (capture antibody), 2) an antibody directed against the protein of interest (anti-AQP2 or anti-NCC), 3) a HRP-conjugated antibody against the anti-AQP2 or anti-NCC antibody, and 4) a Europium-conjugated anti-CD9 antibody. We used two conjugated antibodies to allow quantification of both the protein of interest and CD9 (as uEV marker). Because our anti-AQP2 and anti-NCC antibodies are directed against an intracellular epitope, our uEV immunoassay required the use of a detergent. We tested various detergents in different concentrations and with varying incubation times, of which 0.01% SDS for 10 min resulted in the most optimal signal-to-noise ratio ( Fig. 2A) . A recent study that determined the lysis sensitivity in EV subpopulations also showed that low concentrations of SDS (0.01%) or Triton X-100 (0.025%) were most effective (15) . Subsequently, we validated our uEV immunoassay by selectively removing one of the antibodies, which resulted in loss of signal (Fig. 2B) . In this set of experiments we also confirmed the requirement of the detergent because the signals for AQP2 and NCC were lost when the detergent was not added. The CD9 signal, however, remained intact because the anti-CD9 antibody is directed against an extracellular domain of the protein. No loss of CD9 signal occurred when the detergent was added to the uEV immunoassay, suggesting the detergent did not result in disintegration of bound uEVs and loss of membrane fragments during subsequent washing steps. To be practical clinically, it should be possible to use the uEV immunoassay on spot urines instead of 24 h urine. Clinically, spot urines are routinely used for diagnostic purposes, for example, by using the protein-tocreatinine ratio, which shows excellent correlation with 24 h urine protein (5) . At present, urine creatinine is the most commonly used parameter to normalize uEV protein abundances, assuming that the concentration of the urine sample correlates with uEV number. To test this assumption, we compared urine creatinine concentration with CD9 signal and observed an excellent correlation (Fig. 2C) . This also implies that, with the current uEV immunoassay setup, it is no longer necessary to measure urine creatinine separately. It remains to be studied whether urine creatinine and CD9 truly correlate with uEV number, for example, by nanoparticle tracking analysis (14) . The signals for AQP2, NCC, and CD9 remained stable in serial dilutions (Fig. 2D) , suggesting AQP2-to-CD9 and NCC-to-CD9 ratios can be used as proxy for the abundance of the protein of interest normalized for uEV number. The coefficients of variance for the uEV immunoassay were 5.6% for AQP2 and 3.3% for NCC up to eightfold dilutions. All of these experiments were also performed with uEVs isolated by ultracentrifugation, which gave similar results (data not shown).
Application of uEV immunoassay in physiological and pathophysiological settings. To test whether the uEV immunoassay was capable of detecting physiological and pathophys- iological changes in AQP2 and NCC, we tested it in normal subjects and patients (Figs. 3 and 4) . First, we performed a water-loading experiment in healthy subjects after overnight thirsting. As expected, urine osmolality reflected maximally concentrated urine during thirsting and maximally dilute urine after water loading (Fig. 3A) . Urine osmolality is determined by the degree of water reabsorption in the collecting duct through AQP2 water channels, which are stimulated by vaso- Fig. 3 . Application of uEV immunoassay in physiological AQP2 and NCC regulation. A: urine osmolality (means Ϯ SE) during thirsting and water loading in four healthy subjects. Spot urine samples were measured in four subjects at the following 5 time points: 12 and 14 h after thirsting (T1 and T2) and 2, 3, and 5 h after water loading (WL1-3). *P Ͻ 0.05 by paired t-test. B: representative immunoblot from one of the participants of AQP2 and NCC in uEVs isolated by ultracentrifugation. In addition, average densitometry of immunoblots from all participants (n ϭ 4) is shown at the different time points (means Ϯ SE). *P Ͻ 0.05 by paired t-test compared with T2 after setting all individual T2 values to 1. C: AQP2/CD9 and NCC/CD9 ratios obtained with the uEV immunoassay from urine samples of the water-loading experiments (means Ϯ SE). *P Ͻ 0.05 by paired t-test compared with T2 after setting all individual T2 values to 1. D: correlations of AQP2/UCreat vs. AQP/CD9 and NCC/UCreat vs. NCC/CD9 were plotted to compare immunoblotting of uEVs isolated with ultracentrifugation and results from uEV immunoassay. pressin (9) . More recently, vasopressin was also shown to activate NCC (10) . We first analyzed AQP2 and NCC expression in uEVs during the water-loading experiment with the conventional method using immunoblotting of uEVs isolated with ultracentrifugation and normalized by urine creatinine (Fig. 3B ). Even after normalization by urine creatinine, which is another measure of urinary concentration, the decreased abundances of AQP2 and NCC after water loading were clearly visible, and likely represented a decrease in vasopressin levels in response to hypotonicity (9) . We also tested aquaporin-3, which is also regulated by vasopressin, but did not detect it in uEVs (data not shown), possibly because it is present in the basolateral plasma membrane. We analyzed the same urine samples (without ultracentrifugation) with our uEV immunoassay using AQP2/CD9 and NCC/CD9 ratios, again showing the same pattern (Fig. 3C) . The uEV immunoassay correlated with the conventional method for both AQP2 and NCC (Fig.  3D) . The correlation for AQP2 was stronger than for NCC, possibly because a few data points were near the detection limit (dilute urine) or because of differences in the quality of the antibody. To test whether the uEV immunoassay could detect pathophysiological changes in AQP2 or NCC we tested it in patients. We selected patients with inherited or acquired disease in which AQP2 or NCC activity is disturbed, including nephrogenic or central diabetes insipidus, syndrome of inappropriate antidiuresis (SIAD), Gitelman syndrome, and familial hyperkalemic hypertension (FHHt, also called pseudohypoaldosteronism type 2 or Gordon syndrome). For most of these disorders, lower or higher abundances of AQP2 or NCC have been shown by immunoblot in uEVs isolated with ultracentrifugation (2, 8, 11) . We confirmed lower and higher uEV AQP2 abundances in diabetes insipidus and SIAD (Fig. 4A) . Similarly, we confirmed lower and higher uEV NCC abundances in Gitelman syndrome and FHHt. We then tested whether the same results could be obtained with our uEV immunoassay using whole urine and CD9 normalization. Indeed, the uEV immunoassay reliably recapitulated the expected changes in AQP2 and NCC in uEVs in these disorders (Fig. 4B) .
DISCUSSION
We report a novel approach to isolate and analyze uEVs using an immunoassay. Although immunoassays have been used previously for uEVs, these approaches usually concerned the quantification of a single protein (1, 3, 7) . Alvarez et al. used the commercially available ExoELISA to quantify CD9 as a measure of uEV number (1). Duijvesz et al. developed a time-resolved fluorescence immunoassay to quantify the number of CD9 ϩ or CD63 ϩ uEVs as biomarker for prostate cancer (3). The fact that CD9 ϩ uEVs also derive from prostate may be a limiting factor for our uEV immunoassay, since it may skew the AQP2/CD9 or NCC/CD9 ratio and may yield different results in men. However, in the study by Duijvesz et al., the number of CD9 ϩ uEVs only increased after digital rectal examination (3), suggesting this limitation is minimal. Isobe et al. developed an ELISA to quantify both total and phosphorylated NCC in uEVs (7) . However, because they did not use a capture antibody to isolate uEVs, their approach still required ultracentrifugation. Oosthuyzen et al. used a different approach by adding a fluorescently labeled AQP2 antibody to whole urine and then using a nanoparticle tracking device to quantify AQP2 ϩ uEVs (14) . By doing so, they confirmed an increase in AQP2 ϩ uEVs after desmopressin in normal mice and patients with central diabetes insipidus. The studies by Isobe et al. and Oosthuyzen et al. still required normalization by urine creatinine because no uEV marker was quantified (7, 14) .
We believe our uEV immunoassay may be used as template for other proteins of interest. This requires the confirmation that the protein of interest is indeed present in CD9 ϩ uEVs. Previous immunohistochemical studies in human kidneys demonstrated high CD9 but low CD63 expression (20) . In our study CD9 ϩ uEVs contained both AQP2 and NCC (Fig. 1A) , suggesting CD9 must be expressed in the distal convoluted tubule and collecting duct. If anti-CD9 will be used as capture antibody in future studies, it would be important to know which tubule segments express CD9. Alternatively, an antibody against AQP2 or NCC may be used as capture antibody to isolate tubule-specific uEVs, but this would require the Fig. 4 . Application of the uEV immunoassay in disorders with disturbed AQP2 or NCC regulation. A: AQP2 and NCC were immunoblotted in uEVs isolated with ultracentrifugation. Urine samples were collected from healthy subjects (n ϭ 4) and patients with central (CDI, n ϭ 2) or nephrogenic (NDI, n ϭ 2) diabetes insipidus, syndrome of inappropriate antidiuresis (SIAD, n ϭ 2), Gitelman syndrome (GS, n ϭ 2), and familial hyperkalemic hypertension (FHHt, n ϭ 1). See MATERIALS AND METHODS for details. The second NDI patient did have a visible glycosylated AQP2 band that ran at a higher molecular weight, which may be due to the type of the mutation (mutation analysis pending). B: AQP2/CD9 and NCC/CD9 signals obtained with uEV immunoassay using the urine samples from the healthy subjects and patients. development of antibodies targeting the extracellular domains of these proteins. Another consideration is that the pathophysiological setting by itself may change the number of CD9 ϩ uEVs (3). Although there may be a subpopulation of CD9 Ϫ vesicles that contains AQP2 or NCC, our uEV immunoassay results correlated with the ultracentrifugation method, which isolates all uEVs (Fig. 3D) . We believe our method is most suitable for plasma membrane-associated proteins, since cytosol-derived proteins within uEVs are likely lost after lysis, although this remains to be tested. In summary, we report a novel approach to analyze uEVs that circumvents existing isolation and normalization issues and that detects anticipated changes in physiological responses and clinical disorders.
